RxDoctor Payments Data

Drory Tendler, MD

Clinical Cardiac Electrophysiology · Chandler, AZNPI 1679576177

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $55,440 of the $57,297 with a category attached, or 96.8%. Medtronic accounts for 79.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $24,060 and has fallen 90.1% since, to $2,384 in 2025.

$57,297in general payments, 2019–2025

Across 72 payments — averaging $795.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$46K
  • Boehringer Ingelheim$11K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$158
  • Novartis$141
  • Stryker$73
  • Boston Scientific$61
  • plus $269 from 9 others
$356,924in research payments, 2019–2025

Across 131 payments — averaging $2724.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$356K
  • Microport CRM USA Inc$775

What the payments were for

  • Speaking & faculty fees$55,44097%
  • Travel & lodging$7261%
  • Food & beverage$1,1242%
  • Education$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,297 in reported general payments places this provider in the 70th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$248,330
Medicare patients
422
Services billed
3,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$176,061
XareltoRivaroxaban36$45,942
Dofetilide183$35,491
Flecainide Acetate331$18,220
Propafenone Hcl ErPropafenone Hcl23$4,270
SotalolSotalol Hcl94$2,400
Amiodarone Hcl105$1,956
Mexiletine Hcl18$1,707
Metoprolol Succinate87$1,414
Metoprolol Tartrate63$767
Potassium Chloride22$420
Losartan Potassium13$246
Carvedilol30$216
Furosemide42$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$176,061132 claims
Johnson & JohnsonXarelto$51$45,94236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →